| Name | Title | Contact Details |
|---|
Cydan Development is an orphan drug accelerator that identifies and de-risks programs with therapeutic and commercial potential.
Intabio provides an analytical platform to transform and accelerate the development of biotherapeutic drugs by enabling early product quality characterization and producing profound efficiency gains across all stages of biopharmaceutical development and manufacturing.
At Quantum-Si we have a created a very unique environment where bright, highly committed individuals are given the freedom, ownership, and resources to solve tough problems and be the first to do new science. We are fully-funded by successful founders so employees can focus on creating, building, learning, and getting to market products that will change the world.
Merrimack is a biopharmaceutical company discovering, developing and preparing to commercialize innovative medicines paired with companion diagnostics for the treatment of cancer. Merrimack seeks to gain a deeper understanding of underlying cancer biology through its systems biology-based approach and develop new insights, therapeutics and diagnostics to improve outcomes for cancer patients. Merrimack has multiple oncology therapeutics in clinical development and additional candidates in late stage preclinical development. Merrimack has a New Drug Application under review for its lead product candidate, MM-398, for the treatment of patients with metastatic adenocarcinoma of the pancreas who have been previously treated with gemcitabine-based therapy.
We are committed to helping people with severe, chronic cardiovascular diseases realize the promise of patient-specific, expanded multicellular therapy.